Institute of Medical Biology, Chinese Academy of Medical Sciences is the lead sponsor of 8 current clinical trials in our China register. 1 is recruiting patients now. The most common phase is Phase 1. The drugs named most often in its trials are DTaP, DTacP and MMR vaccine. The most-studied condition is Influenza, Human.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Phase I Clinical Trial of Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine
NCT06184542 · ClinicalTrials.gov ↗ · Diphtheria, Tetanus, Pertussis
|
Phase 1 | Recruiting | 2023-12 | China |
|
Phase III Clinical Trial of Quadrivalent Influenza Virus Split Vaccine
NCT06800950 · ClinicalTrials.gov ↗ · Influenza, Human, Influenza, Human Prevention, Influenza a
|
Phase 3 | Not yet open | 2025-02 | China |
|
Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine
NCT07418372 · ClinicalTrials.gov ↗ · Tetanus, Diphtheria and Acellular Pertussis Vaccination, Tetanus, Diphtheria
|
Phase 1/2 | Not yet open | 2026-03 | China |
|
Phase I Clinical Trial of Enterovirus Type71 - Coxsackievirus Type A16 Bivalent Vaccine
NCT07326878 · ClinicalTrials.gov ↗ · Hand, Foot and Mouth Disease (HFMD), HFMD, Hand, Foot and Mouth Disease
|
Phase 1 | Not yet open | 2025-12 | China |
|
Study of Concomitant Administration of the sIPV and DTaP or MMR
NCT06920069 · ClinicalTrials.gov ↗ · Polio, Diphteria, Tetanus and Pertussis, MMR Vaccine
|
Phase 4 | Not yet open | 2025-05 | China |
|
Phase IV Study of Concomitant Administration of the sIPV and HepA
NCT06460545 · ClinicalTrials.gov ↗ · Polio, Hepatitis A
|
Phase 4 | Not yet open | 2024-06 | China |
|
Study on the Persistence of Immunity Following EV71 Vaccination
NCT07144202 · ClinicalTrials.gov ↗ · Hand, Foot, and Mouth Disease, Hand, Foot, and Mouth Disease (HFMD)
|
Observational | By invitation | 2025-08 | China |
|
Phase I Clinical Trial of Quadrivalent Influenza Virus Split Vaccine
NCT06622590 · ClinicalTrials.gov ↗ · Influenza, Human, Influenza a, Influenza Type B
|
Phase 1 | Active, closed | 2024-10 | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 8 | 1 |
A trial with sites in more than one country appears in each of those registers.
| Sponsor | Trials |
|---|---|
| Anhui Zhifei Longcom Biologic Pharmacy | 1 |
Sponsors with the most current trials registered for this condition.
Institute of Medical Biology, Chinese Academy of Medical Sciences is the lead sponsor of 8 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of its 8 ClinicalTrials.gov trials is recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 4 drugs and biologicals as interventions. The most frequent are DTaP (2), DTacP (1), MMR vaccine (1) and SIPV (1). The number in brackets is how many of its trials name each drug.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.